Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx

Executive Summary

A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.

You may also be interested in...



ICER Will Explore Link Between Reasonable Drug Pricing And ‘Fair’ US Formulary Policies

Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.

ICER Study On Coverage 'Fairness' Could Inform Manufacturer Pricing vs Benefit Design Debate

Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.

Amgen Continues To Feel COVID-19 Sales Impact In Q1

Patients’ COVID-19 anxiety continues to keep them from seeking treatments for psoriasis, migraine and even cancer, Amgen said, blaming the pandemic for much of its 4% decline in first quarter revenue.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel